Evidence map›Paper›PMID 39772076›Full record

ArticleVaccines2024

Stakeholder Consultation Workshop on the Perceived Value of Thermostable Vaccines to Relieve Program Barriers: A Case Study from Côte d'Ivoire.

Anna-Lea Kahn, Dijana Spasenoska, Kouadio Daniel Ekra, Soplé Ruth Coulibaly, Kossia Yao, Sié Kabran Kouadio, Aminatou Sar, Joanie Robertson

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anna-Lea KahnWorld Health Organization (WHO) Headquarters, Avenue Appia 20, 1211 Geneva, Switzerland.ORCID 0000-0001-8565-2814
Dijana SpasenoskaWorld Health Organization (WHO) Headquarters, Avenue Appia 20, 1211 Geneva, Switzerland.ORCID 0000-0003-3640-4405
Kouadio Daniel EkraExpanded Program on Immunization (EPI), Ministry of Health, Abidjan, Côte d'Ivoire.
Soplé Ruth CoulibalyExpanded Program on Immunization (EPI), Ministry of Health, Abidjan, Côte d'Ivoire.
Kossia YaoExpanded Program on Immunization (EPI), Ministry of Health, Abidjan, Côte d'Ivoire.ORCID 0009-0005-4362-7756
Sié Kabran KouadioWorld Health Organization (WHO) Country Office, Abidjan, Côte d'Ivoire.
Aminatou SarUnited Nations Sustainable Development Group, Cotonou 01-3621, Benin.
Joanie RobertsonPATH-Headquarters, Seattle, WA 98121, USA.ORCID 0000-0002-6648-2976

Funding

Gates Foundation INV-004127World Health Organization 001
6 · The paper itself

Abstract

backgroundPersistent inequities in access to vaccinations pose challenges for immunization programs worldwide. Innovations facilitating vaccine delivery, such as leveraging vaccine thermostability through a Controlled Temperature Chain (CTC), have emerged as a potential solution to increase coverage in low- and middle-income countries (LMICs) countries such as Côte d'Ivoire, reducing dependence on the cold chain and improving vaccine delivery efficiency. However, the added value of thermostable vaccines and their integration into national immunization programs is under-recognized by stakeholders. This consultation aimed to convene key immunization stakeholders in Côte d'Ivoire in order to examine their perceptions regarding the value of vaccine thermostability to address barriers to outreach and equity in immunization programs.

methodsA novel workshop model involving structured group discussions was used to document the viewpoints of national stakeholders representing different areas of the immunization program. They prioritized barriers undermining coverage and equity in their country and explored the potential impact of CTC on the immunization program in the context of thermostable vaccines. The vaccines discussed were for Hepatitis B, Human Papillomavirus, and Meningitis.

resultsThe workshop outcomes highlighted the context and vaccine-specific variation of the importance of certain barriers, emphasizing the need for tailored strategies. The barriers considered most likely to be alleviated by vaccine thermostability were under the categories of human resource management, vaccine supply and logistics, and services delivery. The least relevant category of barriers concerned demand generation.

conclusionsThe consultation provided valuable insights into stakeholder perspectives, priorities, and conditions for the effective integration of thermostable vaccines, informing future product development and policy decisions to optimize vaccine delivery and address immunization challenges in LMICs.

Indexed as

controlled temperature chainCôte d’Ivoireinnovation uptakestakeholder perceptionssupply chain efficienciesthermostable vaccinesvaccine delivery

Identifiers

PMID39772076
PMCPMC11679961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.